News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-submits-biologics-license-application-n-803-plus-bcg?field_nir_news_date_value[min]=

ImmunityBio, Inc. @ImmunityBio Join us at the 2022 American Society of Clinical Oncology ( @ASCO Annual Meeting in Chicago, June 3-7. We will be presenting data from two #clinicaltrials for bladder and pancreatic cancers. See you at Booth number: 26135 https://info.immunitybio.com/asco2022 #ASCO #Oncology #CancerResearch https://mobile.twitter.com/immunitybio/status/1527662941327310849

ImmunityBio, Inc. @ImmunityBio 13. Mai IL-15 superagonists are key to potent activation of immune response against cancers; N-803 demonstrating that principle in bladder, pancreatic tumors.

ImmunityBio, Inc. @ImmunityBio 15 Mai #ICYMI: In an interview with @NashvillePost Dr. Sam Chang, @UroCancerMD of @VUMChealth discussed latest data from #BladderCancer trial QUILT 3.032 and how it fills an unmet need for an immunotherapy that helps to fight the cancer. #AUA22

ImmunityBio, Inc. @ImmunityBio 14. Mai In case you missed Dr. Karim Chamie’s #AUA22 presentation today on Phase 3 trial data assessing IL-15RαFc superagonist N-803 (Anktiva) and BCG for patients with BCG-unresponsive #NMIBC, check out UroToday’s coverage of it. @WallisCJD @UCLAUrology https://bit.ly/3L7cuk0

ImmunityBio, Inc. hat retweetet Alexander Kutikov MD @uretericbud 13. Mai 71% response with median duration of response of 2 years for BCG unresponsive CIS patients receiving N-803. Also fantastic response for papillary patients. Presented by Karim Chamie @UclaUrology Extremely well-tolerated. #aua22 #bladdercancer

Endgültige klinische Ergebnisse der zulassungsrelevanten Studie mit IL-15R&[alpha]Fc Superagonist N-803 mit BCG bei BCG-unresponsivem nicht-muskelinvasivem Blasenkrebs (NMIBC) CIS und papillären Kohorten: https://www.urotoday.com/conference-highlights/2022-annual-meeting/aua-2022-bladder-caner/137101-aua-2022-final-clinical-results-of-pivotal-trial-of-il-15r-alpha-fc-superagonist-n-803-with-bcg-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-nmibc-cis-and-papillary-cohorts.html

Auf der offiziellen Seite des Weißen Hauses: "Access to Advanced Health Institute and Immunity Bio:  commit to manufacturing next-generation T-Cell vaccines for pandemic preparedness that are stable at room temperature, rapidly modifiable to address current and emergent pathogens, and provide potent, broad and durable protection in sub-Saharan Africa at the billion dose scale by 2025.  Commit to bringing the latest immune-stimulating cell therapy and vaccine technology through clinical trials and centers of excellence to develop licensed vaccines and breakthrough immunotherapies that address the pandemics of infectious disease and cancer around the Globe.  Committed to expend $1 billion USD over the next 5 years to produce billions of doses of vaccines, fusion proteins, and natural killer cell therapy at our million square feet of 11 plants we currently own globally." https://www.whitehouse.gov/briefing-room/statements-releases/2022/05/12/2nd-global-covid-19-summit-commitments/

Formular 10 Q: https://www.marketscreener.com/amp/quote/stock/IMMUNITYBIO-INC-23160241/news/IMMUNITYBIO-INC-MANAGEMENT-S-DISCUSSION-AND-ANALYSIS-OF-FINANCIAL-CONDITION-AND-RESULTS-OF-OPERAT-40350312/ Unter Anderem (nach meinem Verständnis) mit Hinweis auf BLA-Einreichung voraussichtlich innerhalb von 10 Tagen.

Dr. Pat Soon-Shiong @DrPatSoonShiong A possible solution to #COVID, a T cell based vaccine. This study shows the path. https://mobile.twitter.com/drpatsoonshiong/status/1522610115618107393

ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-present-data-multiple-clinical-trials-2022-american?field_nir_news_date_value[min]=

ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-first-participants-have-been-enrolled-lung?field_nir_news_date_value[min]=

9/21 Investigator Karim Chamie, M.D., Associate Professor of Urology at UCLA. “The AUA-FDA workshop set a lofty, clinically meaningful benchmark: 30% of patients receiving treatment for their BCG-unresponsive bladder cancer remaining disease-free 18–24 months. Unfortunately, none of the FDA-approved (or under FDA evaluation) agents have come close to the goal; by 12 months, only 20% of patients are disease-free. But for the first time, we now have a product with N-803 + BCG that has hit the AUA-FDA 30% 18-month milestone. With its well-tolerated safety profile, I am confident that N-803 + BCG will make a meaningful impact on the lives of patients with BCG-unresponsive bladder cancer.”

"Daran wird gearbeitet Impfstoffe der kommenden Generation könnten jedoch nicht nur das Spike-Protein, sondern andere, weniger variable Bereiche des Virus als Ziel haben. Noch in diesem Jahr möchte das US-Unternehmen ImmunityBio zum Beispiel einen Covid-19-Impfstoff der zweiten Generation auf den Markt bringen, der eine Immunreaktion gegen das Spike-Protein und das sogenannte Nucleocapsid aufbaut. Das Nucleocapsid ist ein Protein, das an der Verpackung des Virus-Erbguts beteiligt ist und sich weniger stark verändern kann. Peter Kremsner hält den zweiten Ansatz für die theoretisch bessere Variante. Ob die Entwicklung gelingt, ist allerdings bisher offen. "Der Wunsch nach einem universellen Impfstoff ist sicher berechtigt, einfach umzusetzen ist er aber nicht", sagt der Direktor des Instituts für Tropenmedizin an der Universität Tübingen."

Suche nach dem Super-Impfstoff https://www.google.com/amp/s/www.ingolstadt-today.de/amp/5923342